Artesunate and Sulfamethoxypyrazine-Pyrimethamine for Malaria Treatment
Author Information
Author(s): Adam Ishag, Magzoub Mamoun, Osman Maha E, Khalil Insaf F, Alifrangis Michael, Elmardi Khalid A
Primary Institution: Faculty of medicine, University of Khartoum, Sudan
Hypothesis
The study investigates the efficacy of a fixed-dose 24-hour regimen of artesunate plus sulfamethoxypyrazine-pyrimethamine compared to a loose combination for treating uncomplicated Plasmodium falciparum malaria.
Conclusion
Both regimens of AS+SMP were effective and safe for the treatment of uncomplicated P. falciparum malaria in eastern Sudan.
Supporting Evidence
- The study included 73 patients who completed the 28-day follow-up.
- Cure rates were 92.3% for the fixed regimen and 97.1% for the loose regimen.
- Mild drug-related adverse effects were reported in 4.1% of patients.
Takeaway
Doctors tested two ways to give medicine to treat malaria, and both worked well, but the simpler method might help patients take their medicine better.
Methodology
The study compared the efficacy of fixed co-formulated artesunate-sulfamethoxypyrazine-pyrimethamine administered every 12 hours for 24 hours with a loose combination given every 24 hours for 3 days.
Limitations
The study was small-sized, and larger studies are needed to confirm the findings.
Participant Demographics
73 patients with uncomplicated P. falciparum malaria, including 9 children under five years of age.
Statistical Information
Statistical Significance
p > 0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website